Joining forces with academia to discover novel chemistry approaches

We have been partnering with the Max-Planck Society and consortium companies for several years. In 2014, we established a chemistry ‘satellite unit’ for cardiovascular and metabolic diseases at the Max Planck Institute of Molecular Physiology in Dortmund, Germany. Here, AstraZeneca scientists are working side-by-side with academic researchers to study new modalities chemistry. This novel strategic alliance aims to discover innovative approaches to drug discovery by combining the strengths of industry and academia. Our focus is on novel chemistry and chemical biology in areas of new modality chemistry such as stabilised peptides, macrocycles and conjugation chemistry.